[CAS NO. 1172133-28-6] HO-3867
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1172133-28-6]
Store
Catalog
SLK-S7501
Brand
Selleck
CAS
1172133-28-6
DESCRIPTION [1172133-28-6]
Overview
| MDL | MFCD28143913 |
|---|---|
| Molecular Weight | 464.55 |
| Molecular Formula | C28H30F2N2O2 |
| SMILES | O=C1/C(CN(CC2=CC(C)(C)N(O)C2(C)C)C/C1=C\C3=CC=C(F)C=C3)=C/C4=CC=C(F)C=C4 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1526 mL | 10.7631 mL | 21.5262 mL |
| 5 mM | 0.4305 mL | 2.1526 mL | 4.3052 mL |
| 10 mM | 0.2153 mL | 1.0763 mL | 2.1526 mL |
| 50 mM | - | - | - |
Description
HO-3867, an analog of curcumin, is a selective inhibitor that inhibits its phosphorylation, transcription, and DNA binding without affecting the expression of other active STATs. HO-3867 induces .
Targets
| STAT3 [1] |
In vitro
HO-3867 produces significant cytotoxicity in A2780 and other tested ovarian cancer cell lines, with less toxic to noncancerous ovarian surface epithelial cells. HO-3867 induces G(2)-M cell cycle arrest in A2780 cells and promotes apoptosis by caspase-8 and caspase-3 activation. HO-3867 blocks the JAK/STAT3 pathway in human ovarian cancer cell lines.
In vivo
HO-3867 (100 ppm p.o.) inhibits the growth of ovarian cancer xenograft tumor in mice without any apparent signs of toxicity, and also results in inhibition of pSTAT3 as well as downregulation of the STAT3-targeting proteins. HO-3867 sensitizes cisplatin-resistant ovarian carcinoma through STAT3 inhibition. HO-3867 (100 ppm p.o.) also attenuates left-heart-failure-induced pulmonary hypertension by decreasing oxidative stress and increasing PTEN expression in the lung of rats.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.